Jülich-based SRTD Biotech secures €31.5 million to develop precision mRNA therapies targeting diseased cells
SRTD Biotech, a Jülich-based BioTech startup focused on developing next-generation precision mRNA therapeutics, has completed an oversubscribed €31.5 million Seed financing round. The funding was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also…
Jülich-based SRTD Biotech has secured €31.5 million in Seed financing to advance its development of precision mRNA therapies targeting diseased cells. The funding round was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund co-leading the round. Other investors included Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset.
SRTD Biotech's unique technology utilizes intracellular RNA disease markers to achieve cell-specific mRNA expression, enabling the controlled delivery of therapeutic payloads in diseased cells while minimizing exposure in healthy tissue. Founded in 2019 by Dr. Bernd Hoffmann and Dr. Heribert Bohlen, SRTD plans to employ this technology to create safer, more effective, and differentiated RNA therapies across a wide range of therapeutic areas.
With the new funding, Matthias Alder will become SRTD's Chief Executive Officer, and Dr. Heinz Koeppl will join as Chief Technology Officer. The investment underscores the potential of SRTD Biotech's innovative approach to revolutionize the field of mRNA therapeutics and address unmet medical needs in various diseases.
Rewritten by urgent.news; may contain errors — check the original.
Source: eu-startups.com